|
|
 |
|
Viewing report
|
|
|
|
State of the Pharmaceutical Industry, 2010 - Critical Role of Midsize Pharma
Decision Resources, Inc., Jan 2010, Pages: 46
Will sufficient numbers of Midsize Pharma companies exist in this decade to feed the business development strategies of the pharmaceutical industry? The group of pharmaceutical companies known as Midsize Pharma is becoming critically important to the industry as a whole. Midsize Pharma is a fertile hunting ground for companies looking to grow by consolidation or those looking to cement a stronger position in specialty drugs, emerging markets, and biosimilars/generics. In this report, we assess the health of Midsize Pharma and examine the reasons for the rapid turnover of this group of companies.
Although the biotech industry is largely credited as the innovation engine for the pharmaceutical industry, opportunities also flourish in the Midsize Pharma industry. Large and small pharmaceutical and biotech companies all look to Midsize Pharma as a source for needed licensing, partnering, or acquisition activities. Understanding the landscape and dynamics of the Midsize Pharma industry has become a prerequisite for successful drug development and commercialization in many market sectors and geographies.
Questions Answered in This Report
- We analyze the top 150 pharmaceutical companies in 2008 based on worldwide pharmaceutical sales and categorize them as Big Pharma, Midsize Pharma, or Small Pharma companies.
What is a Midsize Pharma company? A Small Pharma company? What is the relative sales distribution of these companies?
- The world’s top pharmaceutical companies, including Midsize Pharma fi rms, span the globe geographically.
What proportion of Midsize Pharma companies originate in Europe, the United States, and other countries? What proportion of Midsize Pharma companies originate in advanced, developing Asian, newly industrialized Asian, developing Central and Eastern European, and developing African economies?
- Midsize Pharma represents a unique group of companies with diverse characteristics.
What are the Midsize Pharma companies in Japan, Europe, and Asia? What is the focus of these companies and what strategies are they deploying? What are the generics companies and biosimilars companies that are considered to be Midsize Pharma? What are their recent activities and goals?
- We undertook a comprehensive analysis of the Midsize Pharma landscape in 2004 and in 2008. Midsize Pharma is a dynamic and fluid group of companies. In the last four years, which companies have dropped out of the ranks of Midsize Pharma and which companies have become Midsize Pharma firms? What can this analysis tell us about the future pool of Midsize Pharma companies and the relative strength of this sector of the pharmaceutical industry?
Scope
- Experts: Peter Wittner, principal, Interpharm Consultancy; Barrie G. James, Ph.D., principal, Pharma Strategy Consulting; John Ansell, M.A., principal, John Ansell Consultancy.
- Pharmaceutical companies: Top 150 companies based on worldwide pharmaceutical sales in 2008; definition of Big Pharma, Midsize Pharma, and Small Pharma; company distribution by worldwide pharmaceutical sales; geographical distribution of top Big Pharma, Midsize Pharma, and Small Pharma companies; advanced, emerging, and developing country economies as defined by the International Monetary Fund; pharma distribution by country economy, Russia, and the Commonwealth of
Independent States (CIS).
- Big Pharma: 19 companies, worldwide sales comparisons, country of origin, number of blockbusters, largest therapy areas, mega-mergers.
- Midsize Pharma: more than 52 companies, company focus, dynamics of the midsize group of pharma companies, disappearing Midsize Pharma companies, newly minted Midsize Pharma companies.
- Small Pharma: 79 companies, developing Asian companies, Asian Tigers, Japanese companies, generics companies, European companies.
- Asian pharmaceutical companies: Midsize Pharma, Small Pharma, Indian consolidation, market growth, Asian Tigers, company focus, generics, formulations, active pharmaceutical ingredients (APIs), vaccines, nutritional products, biologics, biosimilars, drug discovery and development services (DDDS), contract research and manufacturing services (CRAMs), industrial products, polymers, radiopharmaceuticals, China’s National Drug Reimbursement List, Chinese initial public offerings (IPOs), new chemical entities, super generics.
- Japanese pharmaceutical companies: Relative size based on worldwide sales, business strategies, international growth, generics, biologics, hybrid business model, vaccines, Big Pharma partnering, OTC, consolidation.
- Generic pharmaceutical companies: Major generics companies, relative size based on worldwide sales, Big Pharma’s new affi nity for generics, nature of the relationship between Big Pharma and generics companies, anti-competition activities, authorized generics, reverse payment settlement deals, Federal Trade Commission (FTC) fi ndings, European Commission findings.
- Biosimilar companies: Companies with disclosed biosimilar development programs, potential acquisition targets, business strategies.
- European pharmaceutical companies: Relative size based on worldwide sales, Icelandic financial system, generics, strategies, animal health, OTC, nutraceuticals, drug delivery, formulations, diverse ownership patterns, biologics, APIs, vaccines, specialty pharmaceuticals, biosimilars, branded generics, three game-changing issues, six survival strategies for independence.
Customers who bought this item also bought
Licensing Opportunities: Neurology
Special Report: Successes and Lessons Learned in the Pharmaceutical Industry, 2009
Value-Added Pharma: How to Accomplish the Impossible
State of the Pharmaceutical Industry 2011 - Industry Remodeling Activities
Pharmaceutical Industry Dynamics 2010: Licensing Opportunities: Rheumatology
SPECIAL REPORT: Lessons Learned in the Pharma Industry, 2008
Biosimilar Opportunities: Pipelines and Companies
A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry
Dealmaking and Financing: Mergers and Acquisitions in Key Markets
Big Pharma’s New Licensing Strategies
|
|
|
|
